Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo — Johan Neyts (1993) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo
Shared by
De Clercq Erik
KU Leuven
Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo
Article
1993
en
Authors
+1 more
JN
Johan Neyts
FS
F S Stals
CB
C. A. Bruggeman
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
1989
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): A novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-moloney murine sarcoma virus activity in vivo
Lieve Naesens
,
Jan Balzarini
,
Ivan Rosenberg
,
Antonı́n Holý
,
De Clercq Erik
Article
1989
Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside in vitro and in vivo
Jan Balzarini
,
Piet Herdewijn
,
De Clercq Erik
Article
1998
Inhibitory effect of 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) on hepatitis B virus replication in vitro
Z.J. Gong
,
Sandra De Meyer
,
Chris Verslype
,
Tamara Coopmans
,
A. Soumillion
,
Johan Neyts
,
De Clercq Erik
,
S. H. Yap
Article
1993
Efficacy of oral 9‐(2‐phosphonylmethoxyethyl)‐2,6‐diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice
Lieve Naesens
,
Johan Neyts
,
Jan Balzarini
,
Antonı́n Holý
,
Ivan Rosenberg
,
De Clercq Erik
Article
1998
In Vitro and in Vivo Inhibitory Activity of the Differentiation-Inducing Agent 9-(2-Phosphonylmethoxyethyl)Adenine (Pmea) Against Rat Choriocarcinoma
Sigrid Hatse
,
Lieve Naesens
,
Bart Degrève
,
Michel Vandeputte
,
Mark Waer
,
De Clercq Erik
,
Jan Balzarini
Discussion(0)
No comments yet. Be the first to comment.